2022 World Conference on Lung Cancer (ePosters)-EP08.01-060. Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data

EP08.01-060. Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data

Back to course

Pdf Summary

A recent analysis of data from the ASCO CancerLinQ database explores long-term survival outcomes in non-small cell lung cancer (NSCLC) patients treated with targeted therapy and immunotherapy. The study included 3,911 patients with stage IV disease, with a median age of 65 years and 52% male. Approximately 77% of patients were treated with immunotherapy alone, 21% with targeted therapy, and 3% received targeted therapy followed by immunotherapy. <br /><br />The primary outcome, 5-year overall survival (OS), was investigated. The analysis found that the 5-year survival rates with immunotherapy and targeted therapy were greater than 15% for advanced NSCLC. Notably, Black patients had a significantly better 5-year survival with immunotherapy compared to White patients. <br /><br />Further analysis revealed that females had a significantly higher 5-year survival rate compared to males in the targeted therapy subgroup, but comparable rates to males in the other treatment subgroups. The overall median survival was 1.9 years for immunotherapy, 1.6 years for targeted therapy, and 3.2 years for targeted therapy followed by immunotherapy.<br /><br />The study utilized the ASCO CancerLinQ Discovery dataset and analyzed variables including demographics, tumor stage, histology, and treatments. Univariate association tests were performed to determine the relationship between clinicopathological variables and treatment groups.<br /><br />The analysis was conducted using the SAS 9.4 software, and the Kaplan-Meier method was used to estimate overall survival. Pairwise comparisons were made between treatment groups using log-rank tests.<br /><br />This study highlights the importance of both immunotherapy and targeted therapy in the treatment of advanced NSCLC, with significant improvements in long-term survival rates observed. It also emphasizes the need for further research and understanding of potential disparities in treatment outcomes based on race and gender. The findings contribute to the growing body of knowledge in the field of lung cancer therapy and may inform treatment decisions for NSCLC patients.

Asset Subtitle

Madhusmita Behera

Meta Tag

Speaker Madhusmita Behera

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

non-small cell lung cancer

NSCLC

targeted therapy

immunotherapy

long-term survival outcomes

5-year overall survival

Black patients

White patients

gender differences

treatment disparities